Photo: Times Now
Corbevax, India’s First Heterologous Booster Vaccine For Covid, Approved By DCGI
The Covid-19 vaccine Corbevax, manufactured by BiologicalE in Hyderabad, is the first to be licensed as a heterologous booster in adults by Drugs Controller General of India. Individuals who had Covishield/Covaxin for their first two doses can get Corbevax as their third. Following the booster dosage of Corbevax, neutralizing antibodies against Omicron variation were identified in 91% of individuals who had received Covishield and in 75% who… read-more
Tags: Covid-19, Coronavirus Vaccines, Covaxin, COVISHIELD, Corbevax, Drugs Controller General of India
Courtesy: The Indian Express
Photo: Bharat Biotech Website
DCGI Approves Bharat Biotech's Intranasal COVID-19 Vaccine For Phase III Trials
The Drugs Controller General of India on January 28, approved clinical trials of Intranasal vaccine against COVID-19. Manufactured by Bharat Biotech, the phase III trials will be conducted on 5,000 subjects, who are vaccinated with Covishield or Covaxin, in nine Indian states. If successful after evaluation, the Intranasal vaccine will also be used as booster dose, especially when the nation is fighting COVID-19's new variant Omicron and the… read-more
Tags: Bharat biotech, Intranasal vaccine, Drugs Controller General of India, Hyderabad, Booster shot
Courtesy: Money Control
Photo: DCGI website
DCGI Grants Market Approval To Covishield & Covaxin With Conditions
The Drugs Controller General of India (DCGI) on January 27, granted regular market approval to India's Covaxin and Covishield vaccines against COVID-19. Following SEC's recommendations, the DCGI allowed only hospitals and clinics to purchase the SII's Covishield and Bharat Biotech's Covaxin under the New Drugs And Clinical Trials 2019 Act. However, the authority needs to submit data every six months to the DCGI and update on CoWIN app.
Tags: COVISHIELD, Covaxin, Drugs Controller General of India, INDIAN MARKET, covid-19 vaccines
Courtesy: News 18
